Fetching results...
0 items found

A1160: PROpel: Efficacy of abiraterone + olaparib vs. abiraterone + placebo in the first-line treatment of patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) at baseline

Prof. N.W. (Noel William) Clarke
Clarke N.W.1, Armstrong A.J.2, Thiery-Vuillemin A.3, Oya M.4, Shore N.5, Procopio G.6, Guedes J.D.7, Arslan C.8, Mehra N.9, Parnis F.10, Brown E.11, Schlürmann F.12, Joung J.Y.13, Sugimoto M.14, Sartor O.15, Poehlein C.16, Barker L.17, Degboe A.18, Saad F.19
1The Christie and Salford Royal NHS Foundation Trusts, Dept. of Urology, Manchester, United Kingdom, 2Duke Cancer Institute Center for Prostate and Urologic Cancer, Dept. of Medicine, Durham, United States of America, 3CHRU Besançon Hôpital J Minjoz, Medical Oncology Unit, Besançon, France, 4Keio University School of Medicine, Dept. of Urology, Tokyo, Japan, 5Carolina Urologic Research Center, Dept. of Surgery and Oncology, Myrtle Beach, United States of America, 6Istituto Nazionale Tumori Milano, Dept. of Medical Oncology, Milan, Italy, 7Hospital de Base de São José do Rio Preto, Dept. of Clinical Oncology, São José do Rio Preto, Brazil, 8Izmir Economy University Medical Park Hospital, Dept. of Medical Oncology, Karsiyaka, Turkey, 9Radboud University Medical Center, Dept. of Medical Oncology, Nijmegen, The Netherlands, 10Ashford Cancer Centre Research, Dept. of Medical Oncology, Kurralta Park, Australia, 11University Hospital Southampton, Dept. of Medical Oncology, Southampton, United Kingdom, 12Centre Hospitalier de Cornouaille, Dept. of Medical Oncology, Quimper, France, 13National Cancer Center, Center For Urological Cancer, Goyang-si, South Korea, 14Kagawa University Hospital, Dept. of Urology, Kagawa, Japan, 15Tulane Cancer Center, Dept. of Hematology/Oncology, New Orleans, United States of America, 16Merck & Co., Inc., Clinical Research Oncology, Rahway, United States of America, 17AstraZeneca, Global Medicines Development, Oncology R&D, Cambridge, United Kingdom, 18AstraZeneca, Global Medicines Development, Oncology R&D, Gaithersburg, United States of America, 19Centre Hospitalier de l’Université de Montréal, CRCHUM, Université de Montreal, Dept. of Urology, Montreal, Canada
38th Annual EAU Congress
Date – Time - Location
13 March 2023, 12:30 - 14:00, Pink Area, Coral 6
Abstract Session 61 - Cell biology and novel therapies in prostate cancer
Prostate Cancer, metastatic - Basic Research & Trials, Novel therapies
  • © 2023 European Association of Urology
  • Disclaimer